Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Francisco Quintana Gonzalez

Obstetrics & Gynecology Coto Laurel Pr, PR Medical Doctor

NPI 1164490108 CMS profile 880045

Marginal 506 Local #2, Coto Laurel Pr, PR 00780

Open in the dashboard

General payments

$16,141

77 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Francisco Quintana Gonzalez of Coto Laurel Pr, PR is reported in the CMS Open Payments database as having received $16,141 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $3,964 17
2023 General $9,864 37
2022 General $740 6
2021 General $216 2
2020 General $839 9
2019 General $518 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Francisco Quintana Gonzalez
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Francisco Quintana Gonzalez were reported at $0. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Francisco Quintana Gonzalez Obstetrics & Gynecology median Middle half National median
2019 $518 $172 $62–$391 $163
2020 $839 $94 $36–$222 $114
2021 $216 $136 $42–$369 $132
2022 $740 $160 $50–$433 $149
2023 $9,864 $169 $56–$423 $160
2024 $3,964 $152 $50–$371 $164
2025 $0 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Intuitive Surgical, Inc. $9,612 20 payments
  2. Medtronic, Inc. $3,652 29 payments
  3. Olympus Corporation of the Americas $1,154 12 payments
  4. Applied Medical Resources Corporation $838 4 payments
  5. Roche Diagnostics Corporation $270 2 payments
  6. Gen-Probe Sales & Service, Inc. $229 2 payments
  7. Becton, Dickinson and Company $160 2 payments
  8. Olympus Latin America, Inc. $111 2 payments
  9. Hologic, LLC $100 3 payments
  10. Johnson and Johnson International $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Education $7,000 3 payments
  2. Travel and Lodging $6,891 29 payments
  3. Food and Beverage $2,241 44 payments
  4. Gift $9 1 payment
Products named General payments · program years 2019–2024
  1. DAVINCI XI $7,000 3 payments
  2. Da Vinci Surgical System $2,612 17 payments
  3. LigaSure $2,412 17 payments
  4. ThunderBeat $1,250 13 payments
  5. MC3 NAUTILUS(TM) ECMO OXYGENATOR $1,225 5 payments
  6. GelPOINT V-PATH $475 3 payments
  7. Gelport Laparoscopic System $363 1 payment
  8. Aptima $265 3 payments
  9. cobas 4800 CT/NG Test v2.0 $145 1 payment
  10. CINtec PLUS Cytology $125 1 payment
  11. Other $186 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

40

Median for Obstetrics & Gynecology: 65

Drug cost

$1,347

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

100%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Progesterone Progesterone, Micronized Brand 25 $897
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 15 $450

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record